Cite
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions.
MLA
van Tienderen, Gilles S., et al. “Hepatobiliary Tumor Organoids for Personalized Medicine: A Multicenter View on Establishment, Limitations, and Future Directions.” Cancer Cell, vol. 40, no. 3, Mar. 2022, pp. 226–30. EBSCOhost, https://doi.org/10.1016/j.ccell.2022.02.001.
APA
van Tienderen, G. S., Li, L., Broutier, L., Saito, Y., Inacio, P., Huch, M., Selaru, F. M., van der Laan, L. J. W., & Verstegen, M. M. A. (2022). Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions. Cancer Cell, 40(3), 226–230. https://doi.org/10.1016/j.ccell.2022.02.001
Chicago
van Tienderen, Gilles S., Ling Li, Laura Broutier, Yoshimasa Saito, Patricia Inacio, Meritxell Huch, Florin M. Selaru, Luc J.W. van der Laan, and Monique M.A. Verstegen. 2022. “Hepatobiliary Tumor Organoids for Personalized Medicine: A Multicenter View on Establishment, Limitations, and Future Directions.” Cancer Cell 40 (3): 226–30. doi:10.1016/j.ccell.2022.02.001.